Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LJPC-501 · 1 trial · 4 indications
Response with respect to mean arterial pressure (MAP) at hour 3 after the start of infusion was defined as an increase from baseline of at least 10 mm Hg or an increase to at least 75 mm Hg, without an increase in the dose of background vasopressors.
| Arm | Type | Description |
|---|---|---|
| LJPC-501 (angiotensin II) | EXPERIMENTAL | Treatment arm |
| Placebo (0.9% sodium chloride solution) | PLACEBO_COMPARATOR | Placebo arm |
| Name | Type | Description |
|---|---|---|
| LJPC-501 | DRUG | Treatment arm |
| Placebo | DRUG | PBO |
Inclusion Criteria: 1. Adult patients ≥ 18 years of age with CRH, defined as those who require a total sum catecholamine dose of \> 0.2 mcg/kg/min for a minimum of 6 hours and a maximum of 48 hours, to maintain a MAP between 55-70 mmHg. 2. Patients are required to have central venous access and an ...
LJPC-501 is an investigational small molecule being developed for the treatment of catecholamine-resistant hypotension (CRH), a condition of dangerously low blood pressure that does not respond to standard catecholamine therapy. It is also studied in related conditions including distributive shock, high output shock, and sepsis.
LJPC-501 is a small molecule designed to address catecholamine-resistant hypotension by providing an alternative vasopressor mechanism. Its specific molecular target is not disclosed in the available clinical trial information, but it is being studied in patients who do not respond to catecholamines.
LJPC-501 is being developed by Innoviva, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol INVA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with catecholamine-resistant hypotension.
LJPC-501 is in Phase 3 clinical development. It has completed a Phase 3 study, but it remains investigational and has not been approved by regulatory authorities. The drug is still undergoing clinical evaluation to determine its safety and effectiveness.
LJPC-501 has one completed Phase 3 clinical trial, identified as NCT02338843. This randomized, double-blind, placebo-controlled study enrolled 344 patients with catecholamine-resistant hypotension and related conditions, including distributive shock, high output shock, and sepsis. The trial was conducted across multiple countries.
LJPC-501 is the primary name used in clinical trials and regulatory documents. No alternative names have been reported for this investigational drug. It is distinct from other vasopressor agents currently on the market or in development.